Drug-Target Information
Drug Name Target Name Drug Type Target Type Source Drug MeSHID Interaction Score Drug Status Target Action
ocrelizumab leukocyte surface antigen leu-16 NA Successful target TTD , DGIDB Multiple Sclerosis
Primary Progressive[MeSHID:D020528]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Diffuse Large B-Cell Lymphoma[MeSHID:D016403]
Multiple Sclerosis[MeSHID:D009103]		 21.22 approved unknown
ocrelizumab b-lymphocyte antigen cd20 biotech NA drugbank , DGIDB Multiple Sclerosis
Primary Progressive[MeSHID:D020528]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Diffuse Large B-Cell Lymphoma[MeSHID:D016403]
Multiple Sclerosis[MeSHID:D009103]		 21.22 approved,investigational antagonist,antibody
ocrelizumab leukocyte surface antigen leu-16 NA Successful target TTD , DGIDB Multiple Sclerosis
Primary Progressive[MeSHID:D020528]
Relapse[MeSHID:D012008]
Disruptive
Impulse Control
and Conduct Disorders[MeSHID:D007174]
Diffuse Large B-Cell Lymphoma[MeSHID:D016403]
Multiple Sclerosis[MeSHID:D009103]		 21.22 approved antibody
click here to return to the previous page